Clinical trial · Observational
Venous Thromboembolism and Bleeding in Hospitalized Medical Patients With Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with cancer hospitalized for an acute medical illness have an increased risk of venous thromboembolic events. Although international guidelines suggest the use of thromboprophylaxis in these patients, the recommendations are based on studies which included a percentage of patients with cancer without primarily focusing on this high risk group. Since patients with cancer present an increased risk of bleeding complications it is critical to evaluate the safety of thromboprophylaxis in the cancer group. Recent studies suggest a limited use of thromboprophylaxis in these patients. The aim of this study is to evaluate the use, efficacy and safety of thromboprophylaxis in medical cancer patients hospitalized for an acute medical disease. Design: observational, prospective study Primary end-point: incidence of major and clinically relevant non major bleeding during hospitalization Secondary endpoints: frequency of use, doses and contraindications for pharmacological thromboprophylaxis; venous thromboembolic events up to three months after discharge
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemorrhage | — | UNRESOLVED | — |
| Vein Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Major bleeding and clinically relevant non major bleeding
- timeFrame
- Participants will be followed for the duration of hospital stay, an expected average of 1 week
Secondary outcomes (2)
- measure
- Venous thromboembolism
- timeFrame
- Participants will be followed up to 3 months after discharge, an expected average of 13 weeks
- measure
- Minor bleeding
- timeFrame
- Participants will be followed for the duration of hospital stay, an expected average of 1 week
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * all patients with cancer hospitalized for an acute medical illness Exclusion Criteria: * current use of oral or parenteral anticoagulant treatment * no informed consent to participate
References
Publications (0)
Data not yet available